"As this recently issued patent indicates, AAVLife is building strong intellectual-property protection at the same time we are steadily progressing our R&D toward an urgently needed therapy,” said Amber Salzman, Chief Executive Officer of AAVLife.

Read More:  Key Patent Granted for AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's ataxia